Regeneron reports second quarter 2022 financial and operating results

Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding regen-cov ® (a)(b), revenues increased 20% second quarter 2022 eylea® u.s. net sales increased 14% versus second quarter 2021 to a record $1.62 billion second quarter 2022 dupixent® global net sales(c)(recorded by sanofi) increased 40% to $2.09 billion versus second quarter 2021 second quarter 2022 gaap diluted eps of $7.47; non-gaap diluted eps(a) of $9.77 including unfavorable $1.71 impact from acquired ipr&d charges fda approved dupixent for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis in adults and adolescents; fda priority review granted for prurigo nodularis encouraging preliminary anti-tumor activity observed for novel investigational psmaxcd28 costimulatory bispecific antibody in combination with libtayo® in advanced metastatic castration-resistant prostate cancer strengthened commitment to oncology through purchase of sanofi's stake in libtayo and acquisition of checkmate pharmaceuticals tarrytown, n.y., aug. 3, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced financial results for the second quarter of 2022 and provided a business update.
REGN Ratings Summary
REGN Quant Ranking